Thrivent Financial for Lutherans Has $2.24 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Thrivent Financial for Lutherans lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 1.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 47,696 shares of the company’s stock after buying an additional 473 shares during the period. Thrivent Financial for Lutherans’ holdings in CRISPR Therapeutics were worth $2,241,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Cetera Investment Advisers raised its stake in shares of CRISPR Therapeutics by 451.3% in the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock valued at $2,324,000 after buying an additional 27,915 shares during the period. CWM LLC boosted its holdings in shares of CRISPR Therapeutics by 11,871.1% in the 2nd quarter. CWM LLC now owns 22,386 shares of the company’s stock worth $1,209,000 after purchasing an additional 22,199 shares in the last quarter. Capital Advisors Inc. OK boosted its holdings in CRISPR Therapeutics by 8.1% during the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after acquiring an additional 22,583 shares during the period. Granite Bay Wealth Management LLC purchased a new stake in CRISPR Therapeutics during the 2nd quarter valued at about $2,375,000. Finally, International Assets Investment Management LLC bought a new position in CRISPR Therapeutics during the 3rd quarter valued at approximately $1,825,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In related news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 1.86 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,382 shares of company stock worth $1,917,679. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $50.84 on Thursday. CRISPR Therapeutics AG has a 1-year low of $43.42 and a 1-year high of $91.10. The stock has a market cap of $4.34 billion, a PE ratio of -17.42 and a beta of 1.67. The firm has a fifty day moving average price of $48.02 and a 200 day moving average price of $51.69.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the prior year, the company earned ($1.41) earnings per share. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.2 EPS for the current fiscal year.

Analyst Ratings Changes

CRSP has been the subject of several research reports. Stifel Nicolaus decreased their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Truist Financial decreased their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Finally, StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.